Meeting
2021 ASCO Annual Meeting
Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.
Authors
Yu Sunakawa
Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan
Yu Sunakawa , Satoshi Yuki , Manabu Shiozawa , Toshiki Masuishi , Tomohiro Nishina , Hisateru Yasui , Takashi Ohta , Naoki Takahashi , Hironaga Satake , Akiyoshi Kanazawa , Masahiro Goto , Hideaki Bando , Hiroya Taniguchi , Yoshinaga Okugawa , Kentaro Yamazaki , Hiromichi Ebi , Yukiko Abe , Shogo Nomura , Chiharu Asano , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Clinical Trial Registration Number
UMIN000028616
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3529)
DOI
10.1200/JCO.2021.39.15_suppl.3529
Abstract #
3529
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.
First Author: Satoshi Yuki
Poster
2018 Gastrointestinal Cancers Symposium
The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.
First Author: Satoshi Yuki
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2018 Gastrointestinal Cancers Symposium
TRUSTY: A randomized multicenter phase II/III study of trifluridine/tipiracil and bevacizumab versus irinotecan, fluoropyrimidine, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.
First Author: Takayuki Yoshino